Login to Your Account

Other News To Note

Friday, November 22, 2013

• Lpath Inc., of San Diego, said it used its discovery technology to generate several monoclonal antibody product candidates targeting the leukotriene family of bioactive lipids. Leukotrienes are implicated in numerous inflammatory processes, and the company said the lead antibody, which is designed to bind to and neutralize several different leukotriene isoforms, has shown positive in vivo results and testing is under way in animal models of respiratory diseases, including asthma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription